Aprogen Biologics Salute del bilancio
Salute finanziaria criteri di controllo 4/6
Aprogen Biologics has a total shareholder equity of ₩392.1B and total debt of ₩147.4B, which brings its debt-to-equity ratio to 37.6%. Its total assets and total liabilities are ₩610.8B and ₩218.7B respectively.
Informazioni chiave
37.6%
Rapporto debito/patrimonio netto
₩147.43b
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | ₩23.64b |
| Patrimonio netto | ₩392.09b |
| Totale passività | ₩218.74b |
| Totale attività | ₩610.83b |
Aggiornamenti recenti sulla salute finanziaria
Recent updates
Risks Still Elevated At These Prices As Aprogen Biologics Inc. (KRX:003060) Shares Dive 26%
Jun 20
More Unpleasant Surprises Could Be In Store For Aprogen Biologics Inc.'s (KRX:003060) Shares After Tumbling 28%
Apr 18We Wouldn't Rely On Aprogen pharmaceuticalsInc's (KRX:003060) Statutory Earnings As A Guide
Jan 16Aprogen pharmaceuticals,Inc.'s (KRX:003060) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Dec 20
Is Aprogen pharmaceuticalsInc (KRX:003060) A Risky Investment?
Nov 24Analisi della posizione finanziaria
Passività a breve termine: A003060's short term assets (₩110.5B) do not cover its short term liabilities (₩155.5B).
Passività a lungo termine: A003060's short term assets (₩110.5B) exceed its long term liabilities (₩63.2B).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: A003060's net debt to equity ratio (31.6%) is considered satisfactory.
Riduzione del debito: A003060's debt to equity ratio has increased from 21.4% to 37.6% over the past 5 years.
Bilancio
Analisi della pista di contanti
Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: A003060 has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Previsione Cash Runway: A003060 is forecast to have sufficient cash runway for 6 months based on free cash flow estimates, but has since raised additional capital.